Plasminogen Activator Inhibitor-1 Is a Significant Determinant of Renal Injury in Experimental Crescentic Glomerulonephritis : Journal of the American Society of Nephrology

Journal Logo

Immunology and Pathology

Plasminogen Activator Inhibitor-1 Is a Significant Determinant of Renal Injury in Experimental Crescentic Glomerulonephritis

Kitching, A. Richard*,†; Kong, Yao Z.*; Ru Huang, Xiao*; Davenport, Piers*; Edgtton, Kristy L.*; Carmeliet, Peter; Holdsworth, Stephen R.*; Tipping, Peter G.*

Author Information
Journal of the American Society of Nephrology 14(6):p 1487-1495, June 2003. | DOI: 10.1097/01.ASN.0000065550.13931.00
  • Free


Crescentic glomerulonephritis (GN) is characterized by glomerular fibrin deposition (1,2). Glomerular fibrin deposition is a feature of rapidly progressive GN in both humans and in experimental models (3,4) In experimental systems, this lesion is fibrin-dependent (5,6). Net glomerular fibrin deposition is a balance between activation of the coagulation system and fibrin deposition and fibrin removal by the plasminogen-plasmin system (7,8). Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that inhibits the activity of both tissue type plasminogen activator (tPA - the predominant glomerular plasminogen activator (9)) and urokinase type PA (uPA) (reviewed in references 10 and 11). PAI-1 is upregulated early in the course of experimental immune renal injury (12,13). Inhibition of tPA and uPA by PAI-1 leads to multiple events that favor deposition of fibrin and other matrix proteins, by inhibiting plasmin generation and the direct effects of uPA. PAI-1 has other effects on cell migration and leukocytes that seem to favor recruitment of leukocytes to inflammatory lesions (11). There is some evidence, including studies of in vivo fibrotic interstitial renal injury (14), that PAI-1 has a pathogenetic role in renal disease. Recent reviews have highlighted both the pathogenetic potential for PAI-1 in renal disease and its potential role as a therapeutic target (10,11).

Functional studies of the role of fibrin in crescentic GN have shown that this fibrin deposition is an important mediator of injury (4–6,15). The net amount of fibrin accumulation in glomeruli results from pathogenetic procoagulant effects driven by tissue factor (7,16) and the protective effects of the plasminogen plasmin system (8,12). Studies in mice deficient in components of this system have demonstrated a protective role for endogenous plasmin (generated by the conversion of plasminogen to plasmin by tPA) in experimental crescentic GN (8). Increased glomerular PAI-1 expression has been found in both human and experimental crescentic GN (12,17–19). Given these findings, it is logical that molecules that inhibit plasmin generation, such as PAI-1, would be pathogenetic in crescentic GN. However, this hypothesis has not been tested in vivo.

These studies address the hypothesis that in fibrin-associated immune glomerular injury, PAI-1 is an important determinant of injury, crescent formation, and matrix accumulation. They use mice that have been genetically manipulated to be PAI-1–deficient (PAI-1 −/− mice) or PAI-1 overexpressing (PAI-1 tg mice) in which experimental crescentic GN, a fibrin associated form of immune glomerular injury, had been induced. In addition to studying disease at 14 d, experimental crescentic GN was studied at 28 d to determine whether any effect of PAI-1 on fibrin/matrix deposition and injury could be overcome by other inhibitors of plasmin.

Materials and Methods

Experimental Design

Mice with a genetic deletion of PAI-1 (20,21) on a C57BL/6 × 129/SvJ background, backcrossed once onto a C57BL/6 background (75% C57BL/6, 25% 129/SvJ) were bred in a specific pathogen-free facility (Monash Medical Center, Melbourne, Australia). Mice of an identical genetic background (i.e., 75% C57BL/6, 25% 129/SvJ) bred from the backcross were used as controls. PAI-1 +/− mice were generated by interbreeding PAI-1 −/− and PAI-1 +/+ mice. PAI-1 transgenic mice on a pure C57BL/6 background expressing a murine PAI-1 minigene under a CMV promoter were generously provided by Dr. D. Ginsburg (Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, Michigan). (22) PAI-1 tg mice were bred in a specific pathogen-free facility (Monash Medical Center). Genetically normal pure C57BL/6 mice were used as controls. Male mice aged 8 to 12 wk were used for experiments. Anti-mouse glomerular basement membrane (GBM) globulin was prepared as described previously (23) Mice were sensitized by subcutaneous injection of a total of 2 mg of sheep globulin in 100 μl of Freund complete adjuvant in divided doses in each flank 10 d before challenge with 5 mg of sheep anti-mouse GBM globulin. Renal injury was studied at two time points: 14 d and 28 d after challenge with sheep anti-mouse GBM globulin. Results are expressed as the mean ± SEM. The significance of differences between groups was determined by ANOVA, followed by Bonferroni Multiple Comparison Test for paired comparisons (GraphPad Prism; GraphPad Software Inc., San Diego, CA). For studies involving PAI-1 tg mice (two groups only) the unpaired t test was used.

For studies using mice genetically deficient in PAI-1, the following groups of mice were studied:

  • PAI-1 +/+ mice: baseline (n = 6), GN day 14 (n = 6), GN day 28 (n = 6)
  • PAI-1 +/− mice: baseline (n = 6), GN day 14 (n = 6), GN day 28 (n = 6)
  • PAI-1 −/− mice: baseline (n = 7), GN day 14 (n = 7), GN day 28 (n = 7)

For studies using mice genetically engineered to overexpress PAI-1, the following groups of mice were studied:

  • C57BL/6 mice: baseline (n = 8), GN day 14 (n = 8), GN day 28 (n = 8)
  • PAI-1 tg mice (C57BL/6): baseline (n = 6), GN day 14 (n = 6), GN day 28 (n = 6)

Assessment of PAI-1 Gentoype and Plasma and Renal PAI-1 Levels

PCR based protocols were used to determine the genotype of PAI-1 +/+, PAI-1 +/−, PAI-1 −/−, and PAI-1 tg mice. The PAI-1 transgene was detected as described previously (22). PAI-1 −/−, PAI-1 +/−, and PAI-1 +/+ mice were genotyped by using primers for the wild-type PAI-1 gene (22) and by detecting the presence of the neomycin resistance gene as a marker for the mutant allele (20). The absence of the PAI-1 was confirmed by measurement of PAI-1 protein in plasma via ELISA using monoclonal antibodies generated by immunizing genetically deficient mice as described previously (24). Results are expressed as ng of PAI-1 protein per ml of plasma. For measurement of PAI-1 in renal tissue by ELISA, tissue from mice was homogenized and extracted as described previously by Lijnen et al. (25) and results expressed as pg of PAI-1 per mg of wet weight.

Assessment of Glomerular Crescent Formation and Glomerular Fibrin Deposition

Kidney tissue was fixed in Bouin fixative and embedded in paraffin, and 3-μm tissue sections were cut and stained with periodic acid-Schiff (PAS). A glomerulus was considered to exhibit crescent formation if two or more layers of cells were observed in Bowman’s space. A minimum of 50 glomeruli was assessed to determine the crescent score for each animal. For detection of fibrin in glomeruli, tissue was embedded in Optimal Cutting Temperature Compound, frozen in liquid nitrogen, and stored at −70°C. Immunofluorescence was performed on 4-μm cryostat cut tissue. Glomerular fibrin deposition was assessed on a minimum of 30 glomeruli per mouse using FITC-goat anti-rabbit fibrin/fibrinogen serum (Nordic Immunological Laboratories, Berks, UK), which cross-reacts with mouse fibrin at a dilution of 1:100 and scored semiquantitatively (0 to 3+) using two different scales. First, the proportion of glomeruli staining positive for fibrin in each mouse was assessed. Second, the overall intensity of fluorescence present in each mouse was scored.

Glomerular Leukocyte Accumulation

Kidney tissue was fixed in periodate lysine paraformaldehyde (PLP) for 4 h, washed in 7% sucrose solution, and then frozen in liquid nitrogen. Tissue sections (6 μm) were stained to demonstrate CD3+ cells and macrophages using a three-layer immunoperoxidase technique, as described previously (26,27). The primary monoclonal antibodies were KT3, anti-mouse CD3, which recognizes T cells (American Type Culture Collection [ATCC], Manassas, VA), and M1/70, anti-CD11b, which recognizes macrophages and neutrophils (ATCC). A minimum of 20 glomeruli were assessed per animal, and results were expressed as cells per glomerular cross section (c/gcs).

Assessment of Proteinuria and Serum Creatinine

Urinary protein concentrations were determined by the Bradford method on timed urine collections. Urine was collected for 24 h at baseline and over the last 24 h of an experiment. Serum creatinine concentrations at the completion of experiments (day 14 or day 28) were measured by the alkaline picric acid method using an autoanalyser.

Renal Collagen and Matrix Accumulation

Renal collagen content was assessed by determining total hydroxyproline according to the method of Bergam and Loxley (28). Samples were hydrolyzed in 6 N HCL by incubation at 110°C overnight. The hydrolysate was neutralized with 2.5 M NaOH. Hydrolysates in isopropanol were oxidized by chloramine T then mixed with p-dimethylsaminonbenzaldehyde (25 min, 60°C), and the absorbance was measured at 558 nm. Total collagen was calculated using the assumption that collagen contains 12.7% hydroxyproline by weight. Results were expressed as μg/mg kidney wet weight.


PAI-1 Protein Levels are Undetectable in PAI-1 −/− Mice and Increased in PAI-1 tg Mice

Plasma PAI-1 levels in normal (without GN) PAI-1 +/+ mice (C57BL/6 × 129Sv/J background) were 9.7 ± 1.5 ng/ml (Table 1). PAI-1 protein was undetectable in all PAI-1 −/− mice. PAI-1 +/− mice had intermediate levels of PAI-1 protein (reduced to 30 to 40% of normal). Normal C57BL/6 mice had PAI-1 levels falling between those of PAI-1 +/− and PAI-1 +/+ mice. Mice engineered to genetically overexpress PAI-1 (PAI-1 tg mice) produced significantly more PAI-1 than all other mice (72 ± 8.1 ng/ml).

Table 1:
Plasma levels of PAI-1 protein measured by ELISA in mice without glomerulonephritis

Glomerulonephritis is Less Severe in Mice Lacking PAI-1

Endogenous PAI-1 Mediates Glomerular Crescent Formation and Fibrin Deposition.

Genetically normal PAI-1 +/+ mice developed proliferative GN with glomerular crescent formation and fibrin deposition 14 d after challenge with sheep anti-mouse GBM globulin (Figures 1, B and E; Figure 2). Glomerular crescent formation and fibrin deposition persisted to day 28. PAI-1 −/− mice were significantly protected from glomerular crescent formation at both the day 14 and day 28 time points (Figures 1C and 2A). Renal PAI-1 protein levels progressively increased in PAI-1+/+ mice but remained undetectable in PAI-1−/− mice (Table 2). A modest reduction in crescent formation was observed in PAI-1 +/− mice at day 14, but not at day 28. Fibrin deposition was detected in most glomeruli of PAI-1 +/+ mice, mainly in the glomerular tuft. However, fibrin deposition was absent in over half of glomeruli in PAI-1 −/− mice (Figures 1F and 2B). At the later time point (day 28), there had been no progressive increase in glomeruli affected in PAI-1 −/− mice. In addition to there being fewer glomeruli in which fibrin was detected, overall intensity of fluorescence was decreased in PAI-1–deficient mice (0 to 3+, per mouse) (day 14: PAI-1 +/+ 2.8 ± 0.2, PAI-1 −/− 1.4 ± 0.2; day 28: PAI-1 +/+ 1.8 ± 0.3, PAI-1 −/− mice all a score of 1).

Figure 1.:
Glomerular injury and fibrin deposition in plasminogen activator inhibitor-1 (PAI-1) +/+ and PAI-1 −/− mice with glomerular nephritis (GN) 14 d after the initiation of injury. (A) Glomerulus from a PAI-1 +/+ mouse without GN. (B) PAI-1 +/+ mice developed proliferative crescentic glomerular injury (mean % glomeruli affected, see Figure 2A). (C) PAI-1 −/− mice developed proliferative GN that is significantly less severe than PAI-1 +/+ mice with only occasional crescent formation. (D) Negative immunofluorescence for fibrin in a glomerulus from a PAI-1 +/+ mouse without GN. (E) Significant fibrin deposition in the glomerular tuft of a PAI-1 +/+ mouse with GN. (F) Reduced fibrin deposition in a glomerulus of a PAI-1 −/− mouse with GN. (A through C, periodic acid-Schiff [PAS] stain, high power view; D through F, immunofluorescence, high power).
Figure 2.:
Glomerular crescent formation and fibrin deposition in PAI-1 +/+, PAI-1 +/−, and PAI-1 −/− mice with GN at 14 and 28 d. Open bars represent PAI-1 +/+ mice, gray bars represent PAI-1 +/− mice, and black bars represent PAI-1 −/− mice. Crescent formation (A) and fibrin deposition (B, expressed as the proportion of glomeruli with immunofluorescent fibrin deposits present) are markedly reduced in mice that are genetically deficient in PAI-1. * P < 0.05 versus PAI-1 +/+ mice, ** P < 0.001 versus either PAI-1 +/+ or +/− mice at the same timepoint (ANOVA).
Table 2:
Renal PAI-1 protein levels measured by ELISA in PAI-1 intact and deficient mice with GN

Leukocyte Recruitment Is Diminished in the Absence of PAI-1.

CD3+ T cells and macrophages were detected in glomeruli of genetically normal PAI-1 +/+ mice (Figure 3). While leukocyte numbers were unchanged in PAI-1 heterozygotes, complete absence of PAI-1 resulted in a substantial reduction in both T cells and macrophages at both time points.

Figure 3.:
Glomerular leukocyte accumulation in PAI-1 +/+, PAI-1 +/−, and PAI-1 −/− mice with GN at 14 and 28 d. Open bars represent PAI-1 +/+ mice, gray bars represent PAI-1 +/− mice, and black bars represent PAI-1 −/− mice. T cells (A) and CD11b+ cells (B) are markedly reduced in glomeruli of mice that are genetically deficient in PAI-1. Dotted lines represent values for mice without GN. ** P < 0.001 versus either PAI-1 +/+ or +/− mice at the same time point (ANOVA).

Functional Indices of Renal Injury in the Absence of PAI-1.

Baseline urinary protein and renal function (measured by serum creatinine) were similar in the three experimental groups (urinary protein: 0.4 ± 0.1 mg/d in all groups; serum creatinine: PAI-1 +/+ 17 ± 0.4, PAI-1 +/− 17 ± 0.5, PAI-1 −/− 19 ± 0.4 μmol/L). PAI-1 +/+ and PAI-1 +/− mice had developed significant proteinuria and renal impairment by day 14 of disease. Urinary protein excretion in PAI-1 −/− mice with GN was significantly lower than the proteinuria observed in either PAI-1 +/+ or PAI-1 +/− mice at day 14 and lower than proteinuria in PAI-1 +/− mice at day 28 (Figure 4A). Serum creatinine levels in PAI-1 −/− mice at either day 14 or day 28 were not different from baseline values (Figure 4B).

Figure 4.:
Functional renal injury in PAI-1+/+, PAI-1 +/−, and PAI-1 −/− mice with GN at 14 and 28 d. Open bars represent PAI-1 +/+ mice, gray bars represent PAI-1 +/− mice, and black bars represent PAI-1 −/− mice. (A) Proteinuria is reduced in PAI-1 −/− mice, though this reduction, compared with PAI-1 +/+ mice, reached statistical significance only at 14 d. (B) There was a trend to decreased serum creatinine in PAI-1 −/− mice. The dotted line represents the mean urinary protein excretion (A) and serum creatinine (B) of mice without GN. There was no difference in these baseline values between groups. * P < 0.05 versus PAI-1 +/+ mice and < 0.001 versus PAI-1 +/− mice, ** P < 0.01 versus PAI-1 +/− mice. *** P < 0.001 versus PAI-1 −/− and +/+ mice.

Renal Collagen Content in GN in the Absence of Endogenous PAI-1.

Genetic deletion of PAI-1 did not affect baseline renal collagen levels (Table 3). By day 14 of disease, PAI-1 +/+ mice had developed a 100% increase in renal collagen content, with levels remaining elevated at day 28. Renal collagen content in PAI-1 −/− mice was significantly less that that in PAI-1 +/+ mice at day 14, but this decrease failed to reach statistical significance at day 28. Collagen accumulation in PAI-1 +/− mice was more than in PAI-1 −/− mice but less than PAI-1 +/+ mice at day 14 of GN.

Table 3:
Renal collagen content in PAI-1 intact and deficient mice with GN

Glomerulonephritis is More Severe in Mice Overexpressing PAI-1

Overexpression of PAI-1 Enhances Glomerular Crescent Formation and Glomerular Fibrin Deposition.

Normal C57BL/6 mice developed proliferative and crescentic GN 14 d after challenge with sheep anti-mouse GBM globulin, with glomerular fibrin deposition (Figures 5A, 5C, and 6). Overall, disease in these mice was marginally less than disease in PAI-1 +/+ mice on a mixed 75% C57BL/6 × 25% 129Sv/J background. Crescent formation and glomerular fibrin deposition persisted at day 28. Renal PAI-1 protein was increased in PAI-1 tg mice, most evident at day 14 (Table 4). At day 14, crescentic GN was more severe in PAI-1 tg mice compared with normal C57BL/6 mice (Figures 5B, 5D, and 6). An increased proportion of glomeruli from PAI-1 tg mice was affected by crescent formation and more glomeruli exhibited fibrin deposition. This increased severity of disease persisted at day 28. Overall intensity of fibrin deposition was also increased in PAI-1 tg mice. C57BL/6 mice with GN had moderate fluorescence intensity for fibrin (0 to 3+ [mean ± SEM]: day 14, 1.5 ± 0.2; day 28, 0.6 ± 0.1). Sections from all PAI-1 tg mice developed strong immunofluorescence for fibrin (all 3+) at day 14, which was still moderate in intensity at day 28 (1.6 ± 0.3).

Figure 5.:
Glomerular injury and fibrin deposition in genetically normal C57BL/6 mice and C57Bl/6 PAI-1 transgenic (PAI-1 tg) mice with GN 14 d after the initiation of injury. (A) Significant glomerular injury with some crescent formation was present in C57BL/6 mice with (mean % glomeruli affected see Figure 6A). (B) C57BL/6 PAI-1 tg mice developed accelerated crescentic GN compared with genetically normal mice with more frequent crescent formation. (C) Fibrin deposition in the glomerular tuft of a C57BL/6 mouse with GN. (D) Increased glomerular fibrin deposition in a glomerular from a PAI-1 tg mouse with GN. (A and B, PAS stain, high power view; C and D, immunofluorescence, high power, photographed at the same exposure).
Figure 6.:
Glomerular crescent formation and fibrin deposition in genetically normal C57BL/6 mice and PAI-1 overexpressing (PAI-1 tg) mice with GN at 14 and 28 d. Open bars represent genetically normal C57BL/6 mice, and gray bars represent PAI-1 tg C57BL/6 mice. Crescent formation (A) and fibrin deposition (B, expressed as the proportion of glomeruli with immunofluorescent fibrin deposits present) are increased in mice that genetically overexpress PAI-1. * P < 0.005, ** P < 0.001 versus C57BL/6 mice at the same time point (unpaired t test).
Table 4:
Renal PAI-1 protein levels measured by ELISA in genetically normal C57BL/6 mice and in mice overexpressing PAI-1 (PAI-1 tg mice) with GN

Leukocyte Recruitment Is Enhanced in PAI-1 tg Mice.

Mice that overexpressed PAI-1 demonstrated increased recruitment of T cells and CD11b+ leukocytes into glomeruli compared with genetically normal C57BL/6 mice with GN (Figure 7). This increased leukocyte influx in PAI-1 tg mice persisted at day 28 of disease.

Figure 7.:
Glomerular leukocyte accumulation in genetically normal C57BL/6 mice and PAI-1 overexpressing (PAI-1 tg) mice with GN at 14 and 28 d. Open bars represent genetically normal C57BL/6 mice, gray bars represent PAI-1 tg C57BL/6 mice. T cells (A) and CD11b+ cells (B) are present in increased numbers in glomeruli of mice that genetically overexpress PAI-1. Dotted lines represent values for mice without GN. * P < 0.005, ** P < 0.001 versus C57BL/6 mice at the same timepoint (unpaired t test).

Functional Renal Injury Is Enhanced by PAI-1 Overexpression.

C57BL/6 mice with GN developed significant proteinuria, measured at both day 14 and day 28, with only minor renal impairment, consistent with the degree of glomerular crescent formation in these mice (Figure 8). As with glomerular crescent, formation, fibrin deposition, and leukocyte recruitment, PAI-1 tg mice with GN developed increased urinary protein excretion and renal impairment, evident at both day 14 and day 28.

Figure 8.:
Functional renal injury in genetically normal C57BL/6 mice and PAI-1 overexpressing (PAI-1 tg) C57BL/6 mice with GN at 14 and 28 d. (A) Proteinuria is increased in PAI-1 tg mice. (B) In PAI-1 tg mice, serum creatinine values were significantly increased compared with normal values and C57BL/6 mice with GN. The dotted line represents the mean urinary protein excretion (A) and serum creatinine (B) of mice without GN. There was no difference in these baseline values between groups. * P < 0.005, ** P < 0.001 versus C57BL/6 mice at the same time point (unpaired t test).

Renal Collagen Accumulation Is Accelerated in PAI-1 tg Mice with GN.

Normal C57BL/6 mice and PAI-1 tg mice had similar baseline renal collagen (Table 5), indicating that transgenic overexpression of PAI-1 in the absence of pathologic stimuli does not lead to increased renal collagen content. Compared with C57BL/6 mice, PAI-1 tg mice developed increased renal collagen accumulation at both 14 and 28 d.

Table 5:
Renal collagen content in genetically normal C57BL/6 mice and in mice overexpressing PAI-1 (PAI-1 tg mice) with GN


PAI-1 has major potential pathogenetic effects in inflammatory renal disease, potentially acting on several different mediator systems (10,11). By inhibiting the activity of plasminogen activators and therefore the generation of plasmin, it can inhibit fibrin removal, resulting in enhanced fibrin accumulation. In addition to its capacity to enhance net fibrin deposition, PAI-1 has the capacity to contribute to the accumulation of collagens and other matrix proteins seen in progressive renal disease. PAI-1 limits conversion of plasminogen to plasmin, the active enzyme that may activate matrix metalloproteinases and act directly on matrix to limit collagen matrix accumulation. The increased PAI-1 levels observed in GN may result in increased leukocyte recruitment in GN both directly (14) and via the chemotactic effects of fibrin (29).

The alterations in glomerular crescent formation fibrin deposition and leukocyte accumulation in PAI-1 −/− and PAI-1 tg mice demonstrate an important role for PAI-1 in experimental crescentic GN. Findings of alterations in renal collagen content in PAI-1 −/− and PAI-1 tg mice support recent studies implicating PAI-1 in renal fibrosis (14). Collectively, the current studies suggest that PAI-1 is important in determining the outcome of renal injury. They support the hypothesis that inhibition of PAI-1 is a potential strategy in the therapy of both rapidly progressive GN and other progressive renal diseases.

In the first section of this study, mice genetically deficient in PAI-1 were significantly protected from renal injury in experimental crescentic GN compared with genetically matched PAI-1 +/+ mice on a C57BL/6 × 129Sv/J background. The relatively mild injury in PAI-1 −/− mice did not show a significant “catch up” effect when anti-GBM GN was prolonged to 28 d. The protection afforded PAI-1 −/− mice was most significant in crescent formation, fibrin deposition, leukocyte recruitment, and the accumulation of collagen. A secondary finding in these studies was that PAI-1 +/− mice, (carrying one normal allele and one disrupted allele) showed a modest degree of protection in only some parameters of disease, more evident at day 14. However, no protection was apparent at 28 d. These PAI-1 +/− mice had baseline PAI-1 plasma levels less than half of those of PAI-1 +/+ mice. Assessment of functional plasma PAI-1 activity in PAI-1 +/− mice after endotoxin stimulation has shown significant increases, but not to levels seen in PAI-1 +/+ mice (20). In the current studies, renal PAI-1 levels in PAI-1 +/− mice were similar to those in PAI-1 +/+ mice at day 14. The relative contributions of plasma and tissue derived PAI-1 in immune renal injury remain unclear.

The second section of these studies used mice that are transgenic for PAI-1 and produce several times more PAI-1 than genetically normal C57BL/6 mice. Control mice in these studies also developed crescentic GN, though their degree of injury was less that the PAI-1+/+ mice. There are many potential contributors to the variation in pattern and severity of injury in experimental GN. Several studies have shown that the genetic background and the nature of the T cell response are important (30–32). For this reason, the current studies are presented and considered as two separate studies with separate strain-matched control groups. However, it is interesting to note that basal PAI-1 levels in C57BL/6 mice were less than those in C57BL/6 × 129Sv/J PAI-1 +/+ mice (plasma and renal). C57BL/6 PAI-1 tg mice with increased renal PAI-1 levels developed accelerated disease compared with C57BL/6 mice when measured by a variety of parameters, including crescent formation, fibrin deposition, glomerular leukocyte accumulation, proteinuria, renal impairment, and renal collagen accumulation at both day 14 and day 28.

This form of GN is fibrin-mediated, and fibrin is a major substrate of plasmin. Therefore many of the effects observed in this study are likely to be mediated by the effects of PAI-1 on net fibrin accumulation in the glomerulus. Fibrin is chemotactic for leukocytes (29), and mice deficient in fibrinogen show fewer leukocytes in glomeruli in this model (6). However, the plasminogen-plasmin system has multiple potential roles in leukocyte accumulation in GN. Plasmin itself can be chemoattractant for leukocytes (33) and in obstructive uropathy (presumably not mediated by fibrin) mice deficient in plasminogen showed decreased leukocyte recruitment (34). In contrast, in fibrin-mediated GN, plasminogen-deficient mice showed a marked increase in fibrin deposition and an increase in glomerular leukocytes (8), while uPA −/− mice showed increased leukocytes without increased fibrin deposition (8). In obstructive uropathy, PAI-1 −/− mice have fewer leukocytes; in the same study, PAI-1 was chemotactic for macrophages ex vivo (14). The exact roles of fibrin, plasmin, and PAI-1 leukocyte recruitment in the kidney and the mechanisms by which they exert their effects remain to be fully elucidated.

PAI-1 is a major inhibitor of plasmin via its effects on tPA and uPA. However, other inhibitors of plasmin such as α2–antiplasmin have potential roles in promoting net glomerular fibrin deposition and injury. Studies in mice deficient in α2–antiplasmin do not support a prominent pathogenetic role for this molecule in immune glomerular injury (35). These findings, together with the current and previous studies (8), suggest that in immune glomerular injury, PAI-1, and tPA (as well as plasminogen) are the critical components of the plasminogen–plasmin system that determine net glomerular fibrin deposition.

The results of the current studies seem at first glance to be discordant from those of Dewerchin et al. (36), who found that renal fibrin deposition was not significantly reduced in the absence of PAI-1. However, in the model of acute LPS induced renal injury used in those studies, fibrin deposition was extraglomerular. In the model used in our current studies, fibrin deposition is predominantly glomerular. Analysis of renal fibrinolytic activity after endotoxin injection, as well as renal tPA and uPA activity (by Dewerchin et al. (36)), showed increased renal fibrinolytic activity in PAI-1 −/− mice and preservation of renal tPA activity in PAI-1−/− mice (compared with PAI-1 +/+ mice, when renal tPA activity fell to undetectable levels). These results are consistent with PAI-1 having an important role in protective fibrinolytic activity in murine “anti-GBM GN” as (1) tPA is the major PA in the glomerulus (9); (2) we have demonstrated tPA to be the more important protective PA in glomerular fibrin deposition in murine crescentic GN (8); and (3) PAI-1−/− mice have preserved renal tPA activity and increased total renal fibrinolytic activity (36).

The current studies do not address the relative importance of the potential sources of PAI-1 in crescentic GN. PAI-1 is present in plasma and is produced by a variety of renal cells, including mesangial cells (37,38), endothelial cells (38), and tubular cells (39). It is likely that both tissue-derived and plasma-derived PAI-1 are important in this disease, though it is probable that tubular cell–derived PAI-1 is not particularly important in the glomerular fibrin deposition observed in experimental anti-GBM GN.

There is evidence in human GN that expression of PAI-1 may help determine disease severity. Lupus nephritis, WHO classes III and IV, is more severe in humans homozygous for the PAI-1 5′ gene promoter 4G polymorphism (4G/4G) (40), which, compared with the 5G/5G phenotype, results in increased PAI-1 expression, particularly in response to inflammatory stimuli. Our experimental data that disease severity is increased in PAI-1 tg mice and decreased in PAI-1−/− mice (both strain-matched) support these human observational studies. In summary, the current studies demonstrate that PAI-1 is an important determinant of crescent formation, injury, fibrin deposition. and collagen accumulation in experimental crescentic GN.

Dr. Ginsburg is thanked for providing the PAI-1 tg mice bred and used in these studies. The assistance of Ms. Janelle Sharkey and Ms. Alice Wright is acknowledged. These studies were supported by grants from the National Health and Medical Research Council of Australia (NH&MRC), the FWO, the Interuniversitary Attraction Poles, the Research Fund K.U.Leuven, and European Union.

1. Neale TJ, Tipping PG, Carson SD, Holdsworth SR: Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet 2: 421–424, 1988
2. Kincaid-Smith P: Coagulation and renal disease. Kidney Int 2: 183–190, 1972
    3. Vassalli P, McCluskey RT: Pathogenetic role of the coagulation process in rabbit Masugi nephritis. Am J Pathol 45: 653–677, 1964
    4. Holdsworth SR, Tipping PG: Macrophage-induced glomerular fibrin deposition in experimental glomerulonephritis in the rabbit. J Clin Invest 76: 1367–1374, 1985
    5. Naish P, Penn GB, Evans DJ, Peters DK: The effect of defibrination on nephrotoxic serum nephritis in rabbits. Clin Sci 42: 643–646, 1972
    6. Drew AF, Tucker HL, Liu H, Witte DP, Degen JL, Tipping PG: Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 281: F1157–F1163, 2001
    7. Erlich JH, Holdsworth SR, Tipping PG: Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis. Am J Pathol 150: 873–880, 1997
    8. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 185: 963–968, 1997
    9. Angles-Cano E, Rondeau E, Delarue F, Hagege J, Sultan Y, Sraer JD: Identification and cellular localization of plasminogen activators from human glomeruli. Thromb Haemost 54: 688–692, 1985
    10. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58: 1841–1850, 2000
    11. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209–220, 2002
    12. Malliaros J, Holdsworth SR, Wojta J, Erlich J, Tipping PG: Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int 44: 557–564, 1993
    13. Feng L, Tang WW, Loskutoff DJ, Wilson CB: Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol 3: 1753–1764, 1993
      14. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587–596, 2001
      15. Thomson NM, Moran J, Simpson IJ, Peters DK: Defibrination with ancrod in nephrotoxic nephritis in rabbits. Kidney Int 10: 343–347, 1976
        16. Tipping PG, Dowling JP, Holdsworth SR: Glomerular procoagulant activity in human proliferative glomerulonephritis. J Clin Invest 81: 119–125, 1988
          17. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EK, Sraer JD: Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 33: 55–60, 1990
            18. Moll S, Menoud PA, Fulpius T, Pastore Y, Takahashi S, Fossati L, Vassalli JD, Sappino AP, Schifferli JA, Izui S: Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. Kidney Int 48: 1459–1468, 1995
              19. Keeton M, Ahn C, Eguchi Y, Burlingame R, Loskutoff DJ: Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int 47: 148–157, 1995
                20. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92: 2746–2755, 1993
                21. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D: Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92: 2756–2760, 1993
                  22. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232–237, 1996
                  23. Kitching AR, Huang XR, Turner AL, Tipping PG, Dunn AR, Holdsworth SR: The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol 13: 350–358, 2002
                  24. Declerck PJ, Verstreken M, Collen D: Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 74: 1305–1309, 1995
                  25. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M: Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93: 2274–2281, 1999
                  26. Tipping PG, Huang XR, Berndt MC, Holdsworth SR: A role for P selectin in complement-independent neutrophil- mediated glomerular injury. Kidney Int 46: 79–88, 1994
                  27. Huang XR, Holdsworth SR, Tipping PG: Evidence for delayed type hypersensitivity mechanisms in glomerular crescent formation. Kidney Int 46: 69–78, 1994
                    28. Bergman I, Loxley R: Two improved and simplified methods for the spectrophotometric determination of hyroxyproline. Anal Chem 35: 1961–1965, 1963
                    29. Holdsworth SR, Thomson NM, Glasgow EF, Atkins RC: The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: Studies using glomerular culture and electron microscopy. Clin Exp Immunol 37: 38–43, 1979
                    30. Huang XR, Tipping PG, Shuo L, Holdsworth SR: Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int 51: 94–103, 1997
                    31. Kalluri R, Danoff TM, Okada H, Neilson EG: Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 100: 2263–2275, 1997
                      32. Kitching AR, Tipping PG, Holdsworth SR: IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Eur J Immunol 29: 1–10, 1999
                        33. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF: Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 91: 2005–2009, 1998
                        34. Edgtton KL, Carmeliet P, Kitching AR: Endogenous plasmin is not protective in unilateral ureteric ligation induced renal interstitial fibrosis. Nephrology 7: A 76, 2002
                        35. Kitching AR, Turner AL, Lijnen HR: Endogenous α2-antiplasmin does not enhance fibrin deposition or injury in glomerulonephritis. Nephrology 7: A76, 2002
                        36. Dewerchin M, Collen D, Lijnen HR: Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 86: 640–646, 2001
                        37. Lacave R, Rondeau E, Ochi S, Delarue F, Schleuning WD, Sraer JD: Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int 35: 806–811, 1989
                        38. Xu Y, Hagege J, Mougenot B, Sraer JD, Ronne E, Rondeau E: Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 50: 2011–2019, 1996
                        39. Duymelinck C, Dauwe SE, Nouwen EJ, De Broe ME, Verpooten GA: Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1. Kidney Int 51: 1818–1830, 1997
                        40. Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, Li PK: Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 59: 1520–1528, 2001
                        Copyright © 2003 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.